+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Islet Amyloid Polypeptide"

Islet Amyloid Polypeptide - Pipeline Review, H2 2020 - Product Thumbnail Image

Islet Amyloid Polypeptide - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 50 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

The Islet Amyloid Polypeptide (IAPP) market is a segment of the Endocrine and Metabolic Disorders Drugs market. IAPP is a hormone produced in the pancreas that is involved in glucose metabolism. It is also known as amylin and is associated with Type 2 diabetes. IAPP is used to treat diabetes by helping to regulate blood sugar levels. It is also used to treat obesity and other metabolic disorders. IAPP is available in both injectable and oral forms. It is typically administered as a once-daily injection or as an oral tablet. The market for IAPP is expected to grow due to the increasing prevalence of diabetes and other metabolic disorders. Some companies in the IAPP market include Novo Nordisk, Eli Lilly, Sanofi, Merck, and AstraZeneca. These companies are involved in the development, manufacture, and marketing of IAPP products. Show Less Read more